Compare Intuitive Surgical, Inc. (ISRG) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Synopsys, Inc. — how do they compare? Intuitive Surgical, Inc. trades at $418.94 (market cap $146.76B), while Synopsys, Inc. trades at $503.05 (market cap $95.39B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Synopsys, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Synopsys, Inc. for 71 Days on average.
| ISRG | SNPS | |
|---|---|---|
Market Cap | $146.76B | $95.39B |
Volume | 2,529,814 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $592.85 | $534.56 |
52-Week Low | $332.02 | $367.70 |
Typical Hold Time | 84 Days | 71 Days |
Enterprise Value | $141.54B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue reaching $10.06 billion and net income of $2.86 billion, maintaining impressive profit margins above 28%. Recent expansion into ambulatory surgery centers and international markets like India and Japan provides growth catalysts, though China headwinds present challenges. Technical indicators show bullish momentum with support at $411 and resistance at $417.
ISRG presents a compelling growth story with dominant market positioning in robotic surgery and strong recurring revenue streams. The stock offers 16% upside to the consensus price target of $480.78, supported by 70% analyst buy ratings. Key risks include competitive pressures in robotic surgery and international market volatility. The company's consistent earnings outperformance and expanding global footprint suggest continued growth potential despite near-term headwinds.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, but maintains strong bullish momentum with recent AI-driven partnerships and earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5%, supported by a 72.38% gross margin. Technical indicators show bullish moving averages but overbought RSI levels above 89, with key support at $500 and resistance at $505. Recent announcements with OpenAI and Amazon have driven significant investor optimism and price target upgrades.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus target suggesting 14% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks include high valuation (P/E 87.7) and execution challenges in large-scale partnerships. The stock's proximity to all-time highs requires careful monitoring of earnings delivery and competitive pressures in the EDA market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
